Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Isolyser (OREX)- Any comments -- Ignore unavailable to you. Want to Upgrade?

To: Guy Gadois who wrote (595)	6/15/1999 4:58:00 PM
From: LCWest	Read Replies (1) \| Respond to of 617

Isolyser is in the middle of a major turnaround. I have been a stockholder for years and have been hurt in the wallet. However orex at 3.75 now is completely different animal than orex at 20 was. I bought a large position at 3.00 and in this market it has been a good place to be. The former mgmt team was naive and incompetent. The current ceo and cfo have made the right moves and been accurate on everything they have said. Migo (CEO) has experience in turnaround situations. Recent moves include the serious reduction of debt by outsourcing and selling off non profitable businesses. The co just turned profit Q1. Recent agreement with Cardinal Health/Allegiance is edging the stock higher as it reached 4 today. We are waiting for the details of the deal but rumor has it Isolyser will recieve 30-50 million for the MedSurg division and another 50-100 million in guaranteed orex sales. Pumping this kind of cash into this company makes it debt free and profitable. Also the industrial division of isolyser has much more potential than medical and recently announced an agreement with Delta environmental as well. IMO, when the terms are announced, the 1.1 million shorts have to cover and it becomes marginable look out. Predict 6-8 by August.